MediWound reports Q2 revenue decline, reaffirms 2026 guidance

MediWound (NASDAQ: MDWD ) held its second-quarter earnings conference call on Thursday.

Below is the complete transcript from the call.

APIs provide real-time access to earnings call transcripts and financial data.

Visit to learn more.

Access the full call at Summary MediWound reported a decrease in Q2 2026 revenue to $3.1 million, down from $5.7 million in Q2 2025, primarily due to timing of BARDA-funded development revenue.

Significant progress was made in advancing the EscharEx Phase 3 VALUE trial, with enrollment ongoing and expected completion by Q1 2027, and updated market assessments projecting U.S. peak sales at $1.05 billion.

NexoBrid's U.S. commercial performance strengthened, with Vericel reporting record quarterly revenue, and a new master service agreement with Vericel was signed following a BARDA contract.

The company reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, expecting a revenue boost in the second half from government-funded programs and the Vericel MSA.

Increased investment in research and development was noted, with expenses reaching $5.9 million in Q2 2026, mainly due to the EscharEx VALUE trial.

Management highlighted the strategic importance of collaborations and government contracts, emphasizing the expansion of NexoBrid's applications and manufacturing capabilities.

Full Transcript OPERATOR Good day and welcome to the MediWound second quarter 2026 earnings conference call.

All participants will be in listen-only mode.

Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, you may press star then one on a touchtone phone.

To withdraw your question, please press star then two.

Please note this event is being recorded.

I would now like to turn the conference over to Gaia Shamus from LifeSci Advisors.

Please go ahead.

Gaia Shamus, LifeSci Advisors Thank you, Chloe, and welcome everyone.

Earlier today, pre-market open, MediWound issued a press release announcing financial results for the second quarter ended June 30, 2026.

You may access this press release on the company's website under the Investor tab.

I would ask you to review the full text of our forward-looking statements within this morning's press release.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects or future events or plans, are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.

These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC.

In addition, all forward-looking statements represent our views only as of today, and MediWound assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise.

This conference call is property of MediWound and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.

With us today are Ofer Gonen, Chief Executive Officer of MediWound; Fanny Luxembourg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development.

Following our prepared remarks, we will open the call for Q&A.

Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound.

Ofer Gonen, CEO Thank you, Gaia, and good morning everyone.

During the second quarter we made meaningful progress against our strategic priorities advancing EscharEx and.

Do you hear me? OPERATOR Yes, we can hear you.

Everyone please stand by while I reconnect our speaker.

Thank you.

Pardon me, everyone.